Replication-competent lentivirus (RCL) poses a significant safety concern in lentiviral vector–based therapies, requiring rigorous testing to ensure product safety and regulatory compliance. Traditional cell culture–based detection methods can take up to six weeks to yield results, delaying manufacturing timelines. The QIAcuity RCL Quant Kit enables rapid, sensitive and standardized RCL detection using digital PCR, delivering results in under two hours with high precision and reproducibility. Its duplex assay with internal controls ensures consistent performance even in complex sample matrices, supporting reliable monitoring and faster product release.
Key highlights:
- Fast, digital PCR–based RCL detection that cuts time-to-result from weeks to hours
- High-sensitivity assay with built-in controls for reliable results, even in complex samples
- Standardized, ready-to-use workflow that supports consistent QC and regulatory expectations
Applicable for:
- Cell and gene therapy manufacturing and quality control
- Lentiviral vector process development and release testing
- CDMOs and GMP-compliant analytical laboratories
Download the technical information to learn how digital PCR enables fast, standardized RCL detection with the QIAcuity RCL Quant Kit.